RJFSA
CLRB icon

Raymond James Financial Services Advisors’s Cellectar Biosciences CLRB Stock Holding History

Raymond James Financial Services Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$64.2K Hold
1,000
– – ﹤0.01% 3347
2024
Q2 		$75K Hold
1,000
– – ﹤0.01% 3274
2024
Q1 		$119K Buy
+1,000
New +$108K ﹤0.01% 3199

Other funds holding CLRB

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's CLRB Position: Q3 2024 in Review

Raymond James Financial Services Advisors held its Cellectar Biosciences (CLRB) position steady in Q3 2024 at 1,000 shares worth $64.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3347.

Raymond James Financial Services Advisors first reported a position in CLRB in Q1 2024 and has held it in 3 quarters since. The position peaked at $119K in Q1 2024. 35 funds tracked by Wall St. Rank hold CLRB as of Q3 2024.

  • Raymond James Financial Services Advisors held 1,000 shares of Cellectar Biosciences worth $64.2K as of Q3 2024.
  • Raymond James Financial Services Advisors left its Cellectar Biosciences share count unchanged in Q3 2024.
  • Cellectar Biosciences made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3347 holding.
  • Raymond James Financial Services Advisors first reported a position in Cellectar Biosciences in Q1 2024 and has held it in 3 quarters since.
  • Raymond James Financial Services Advisors's Cellectar Biosciences position peaked at $119K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.